The hypothesis suggests that in the event of NAD(P)H and ATP deficiency in AD, AGEP, or PLE, the administration of PPARG activators such as linoleic acid may serve to address the underlying issue and result in a remission of symptoms or provide effective prophylaxis. Here, PPARG is linked to Alzheimer disease.